<DOC>
	<DOCNO>NCT00938405</DOCNO>
	<brief_summary>This prospective , randomize , double blind , parallel , placebo control clinical trial evaluate efficacy colesevelam HCl reduce LDL subject type 1 diabetes mellitus 12 week treatment period . The aim highlight effect colesevelam LDL cholesterol glycemia type 1 diabetic population . The colesevelam group anticipate demonstrate mean reduction LDL 10 % compare placebo group , indicate A1c glycemic target range CGM reading .</brief_summary>
	<brief_title>Efficacy Colesevelam Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>This prospective , randomize , double blind , parallel , placebo control clinical trial evaluate efficacy colesevelam HCl reduce LDL subject type 1 diabetes mellitus 12 week treatment period . Colesevelam orally administer bile acid sequestrant approve adjunct diet exercise lower incidence hyperlipidemia , important risk factor long term cardiovascular health general population people live diabetes . Use colesevelam show concurrently decrease low density lipoprotein cholesterol ( LDL-C ) A1c patient type 2 diabetes . The exact mechanism unknown . Our research aim highlight effect colesevelam LDL glycemia type 1 diabetic population . This single-center study enroll maximum 40 patient LDL-C &gt; 100 A1c value 6.5-9 % , randomize 1:1 fashion either study drug placebo . Visits conduct screening , baseline , one month , two month , three month . At home , subject take 3.75 gms/day colesevelam HCl placebo throughout study duration . Laboratory analysis perform various timepoints assess A1c , fast lipid panel , c-peptide , glucagon-like-peptide-1 ( GLP-1 ) , glucose-dependent insulinotropic peptide ( GIP ) . Continuous glucose monitoring ( CGM ) measurement obtain patient one week monthly visit ass target range ( ATR ) , within target range ( WTR ) , target range ( BTR ) glucose value time spend hyperglycemic hypoglycemic excursion . The colesevelam group anticipate demonstrate mean reduction LDL 10 % compare placebo group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>All subject stable dos insulin use MDI CSII ( Basal insulin Lantus Levemir ; Bolus Humalog , Novolog , Apidra , Humulin Regular ) , three month prior enrollment . Type 1 diabetes duration &gt; 3 year . 6.5 % ≤ A1c ≤ 9.0 % . Male female ≥ 18 ≤ 65 year age . Ability willingness adhere protocol include multiple daily oral dos study drug placebo weeklong CGM wear . LDLC &gt; 100 mg/dl . Willing adhere colesevelam dosage instruction , include administration drug know interaction least 4 hour prior colesevelam . Females use oral contraceptive contain ethinyl estradiol norethindrone must willing administer dos least four hour prior use colesevelam . Advanced retinopathy need laser procedure vitrectomy . Unstable nephropathy ( serum creatinine &gt; 2.0 mg/dl macroproteinuria ( albumin excretion rate &gt; 200 ug/ min ) . Any unexplained severe hypoglycemia within last six month . BMI &gt; 35.0 . Currently preexist bile acid sequestrant therapy , glyburide , levothyroxine , phenytoin , warfarin . Pregnant , plan pregnancy , use adequate method birth control . Any condition , determine investigator , could make subject unsuitable trial , impair subject 's suitability trial , impairs validity inform consent . Use medication know modify glucose value insulin ( i.e . corticosteroid oral antidiabetic ) . A history bowel obstruction . Serum triglyceride ( TG ) concentration &gt; 500 mg/dL . A history hypertriglyceridemia induce pancreatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>type 1 diabetes mellitus</keyword>
	<keyword>colesevelam</keyword>
	<keyword>LDL</keyword>
	<keyword>cholesterol</keyword>
	<keyword>A1c</keyword>
	<keyword>target range glucose value</keyword>
</DOC>